Eli Lilly and CompanyLLYNYSE
Loading
R&D Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+22.9%
5Y CAGR+17.4%
Year-over-Year Change
Research and development spending
3Y CAGR
+22.9%/yr
vs +9.2%/yr prior
5Y CAGR
+17.4%/yr
Recent acceleration
Acceleration
+13.6pp
Accelerating
Percentile
P100
Near historical high
vs 5Y Ago
2.2x
Strong expansion
Streak
7 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $13.34B | +21.4% |
| 2024 | $10.99B | +18.0% |
| 2023 | $9.31B | +29.5% |
| 2022 | $7.19B | +3.8% |
| 2021 | $6.93B | +16.0% |
| 2020 | $5.98B | +6.8% |
| 2019 | $5.59B | +10.8% |
| 2018 | $5.05B | -0.9% |
| 2017 | $5.10B | -4.0% |
| 2016 | $5.31B | - |